Gelomics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
26
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
6
Gelomics General Information
Description
Developer of advanced 3D cell culture matrices designed to replicate complex tissue environments for research and drug discovery purposes. The company's platform features photocrosslinking technology that allows control over matrix stiffness, compatibility with various cell types, reproducible batch-to-batch results, and fabrication of biomimetic tissue models, enabling academic researchers, pharmaceutical companies, and biotech professionals to conduct more physiologically relevant experiments and advance disease modelling.
Contact Information
Website
www.gelomics.comCorporate Office
- 60 Musk Avenue
- Kelvin Grove
- Brisbane, Queensland 4059
- Australia
Corporate Office
- 60 Musk Avenue
- Kelvin Grove
- Brisbane, Queensland 4059
- Australia
Gelomics Timeline
Gelomics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Accelerator/Incubator | 07-Aug-2025 | Completed | Generating Revenue | |||
| 3. Seed Round | 18-Jan-2024 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 19-Jun-2023 | Completed | Generating Revenue | |||
| 1. Grant | 01-Jan-2019 | $98.5K | Completed | Generating Revenue |
Gelomics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed Preference Shares |
Gelomics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Gelomics Patents
Gelomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025904879-A0 | Multi-zone cell culture well plate | Pending | 16-Oct-2025 | ||
| AU-2025902655-A0 | Photo-crosslinking device, masking arrangement and lighting sub-system | Pending | 26-Jun-2025 | ||
| AU-2022903674-A0 | Modified gelatins, hydrogels | Pending | 02-Dec-2022 | ||
| AU-2023404679-A1 | Modified gelatins, hydrogels, and processes for their production | Pending | 02-Dec-2022 | ||
| EP-4626957-A1 | Modified gelatins, hydrogels, and processes for their production | Pending | 02-Dec-2022 | C08J3/075 |
Gelomics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Gelomics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Google Accelerator | Accelerator/Incubator | |||
| AngelLoop | Angel Group | Minority | ||
| Jelix Ventures | Venture Capital | Minority | ||
| QIC | Sovereign Wealth Fund | Minority | ||
| Brisbane Economic Development Agency | Accelerator/Incubator |
Gelomics FAQs
-
When was Gelomics founded?
Gelomics was founded in 2018.
-
Where is Gelomics headquartered?
Gelomics is headquartered in Brisbane, Australia.
-
What is the size of Gelomics?
Gelomics has 26 total employees.
-
What industry is Gelomics in?
Gelomics’s primary industry is Biotechnology.
-
Is Gelomics a private or public company?
Gelomics is a Private company.
-
What is Gelomics’s current revenue?
The current revenue for Gelomics is .
-
How much funding has Gelomics raised over time?
Gelomics has raised $2.26M.
-
Who are Gelomics’s investors?
Google Accelerator, AngelLoop, Jelix Ventures, QIC, and Brisbane Economic Development Agency are 5 of 6 investors who have invested in Gelomics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
